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ABSTRACT

ARTICLE HISTORY

Objective: To compare the neurodevelopmental outcome of monochorionic-diamniotic twins
(MCDA) with type II selective intrauterine growth restriction (SIUGR-II) managed in utero either
expectantly or with laser.
Materials and methods: Postnatal neurodevelopmental assessment was conducted on the children of patients that had been antenatally diagnosed with SIUGR-II between 16 and 26 weeks
gestational age (GA) and that had been randomly assigned to expectant management (EM) versus laser therapy (LT). The assessment was conducted by trained specialists using the Battelle
Developmental Inventory (BDI-2). BDI-2 total and domain (adaptive, personal–social, communication, motor, and cognitive) composite scores for the appropriately grown (AGA) and growthrestricted (IUGR) twins were compared by treatment arm.
Results: Twenty patients diagnosed with SIUGR had undergone block randomization between
two centers to either expectant management (EM) (6) or laser therapy (LT) (14). The mean (SD)
GA at diagnosis was no different between the EM and LT groups [21.5 (2.0) versus 21.1 (2.8)
weeks, p ¼ .7414, respectively]. However, GA at delivery was significantly lower in the EM versus
LT groups [28.3 (1.8) versus 33.4 (3.8) weeks, p ¼ .0039]. At 6 months, all 20 AGA babies were
alive, whereas only 3/6 (50%) of the IUGR babies in the EM group and 4/14 (29%) in the LT
group were alive (p ¼ .6126). One family in the EM group and two families in the LT group
declined BDI-2 assessment. The mean (SD) age at BDI-2 assessment was no different between
the EM and LT groups [75.6 (14.4) versus 70.7 (18.2) months, p ¼ .5618, respectively]. For the
AGA children, there were no significant differences in total BDI-2 scores for the EM versus LT
[97.4 (10.4) versus 98.0 (19.6), p ¼ .8741], nor in any of the domain composite scores. For the
IUGR children, no statistically significant differences were detected in total BDI-2 scores between
the EM and LT [72.0 (31.1) versus 92.8 (22.1), p ¼ .643], nor in any of the domain composite
scores. The comparison of standardized scores between the AGA and IUGR pairs was significantly different, but within the normal range.
Conclusions: Neurodevelopmental outcomes for SIUGR-II MCDA twins were similarly favorable,
whether managed expectantly or with laser treated. However, the significantly different GA at
delivery (28.3 versus 33.4 weeks, p ¼ .0039, expectant versus laser, respectively) may suggest
improved outcomes in laser-treated patients in a larger cohort.
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Introduction
Selective intrauterine growth retardation (SIUGR) [1]
occurs in approximately 12.5%–25% of all monochorionic pregnancies [2,3]. The condition is defined as an
estimated fetal weight (EFW) of <10th percentile for
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one twin (SIUGR twin), while the other twin is appropriately grown for gestational age (AGA) (EFW
between 10 and 90th percentile) [1,4]. Although SIUGR
may occur from failure of the individual placental territory (IPT) [4] of one twin to satisfy the nutritional
aspects of that fetus [4,5], it may also result from the
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presence of placental vascular anastomoses, despite
an adequate IPT for the SIUGR twin [6,7].
Expectant management of patients with SIUGR may
be associated with an increased risk of adverse perinatal outcome, including prematurity and its attendant
complications [8]. Increased risk for spontaneous
demise of the SIUGR twin may result in the concomitant demise of the AGA twin in up to 40% of cases or
in neurologic damage of the AGA twin in up to 30%
of cases [9–21]. The adverse effects on the AGA twin
resulting from the spontaneous demise of the SIUGR
twin stem from postmortem fetofetal hemorrhage
from the AGA twin to the demised SIUGR twin
through placental vascular communications [15,22].
The risk of an adverse outcome may be higher
depending on the umbilical artery Doppler waveform
of the SIUGR fetus, such that fetuses with persistent
absent end-diastolic velocity (AEDV) (SIUGR type II) are
thought to be at a higher risk than SIUGR fetuses with
umbilical artery forward diastolic flow (SIUGR type I)
[8,23]. Fetuses with intermittent AEDV (SIUGR type III)
are believed to have an unpredictable prognosis [24].
To avoid the potential complications associated with
expectant management, patients with SIUGR are often
asked to consider either termination of pregnancy or
cord occlusion of the SIUGR twin [25].
In 2001, Quintero et al. reported on the feasibility
of performing laser therapy for SIUGR [1] by ablating
the placental vascular anastomoses, similar to the laser
technique described for the treatment of twin–twin
transfusion syndrome (TTTS), namely selective laser
photocoagulation of communicating vessels (SLPCV)
[26]. In that study, 17 patients with SIUGR were managed expectantly and 11 patients were managed with
SLPCV. Both perinatal survival (14/17, 82.4% versus 8/
11, 72.7%, p ¼ .6) and neurological morbidity (3/22,
13.6% versus 0/12, 0%, p¼.5) were comparable
between the groups. However, neurological morbidity
was limited to the expectantly managed group [1].
To examine the potential merit of SLPCV in the
management of SIUGR, our group previously conducted a randomized clinical trial comparing expectant management versus laser therapy in a population
of type II SIUGR patients. The primary aim of the study
was to compare the neurodevelopmental outcome of
the AGA twin in the two groups using the Battelle
Developmental Inventory-2 (BDI-2).

Materials and methods
The study population consisted of children born to
mothers that had been antenatally diagnosed with

type II SIUGR between 16 and 24 0/7 weeks of gestation who had been randomized to either expectant
management (EM) or laser therapy (LT). Inclusion criteria comprised the following: surviving children diagnosed in utero as being members of a monochorionic
diamniotic twin gestation with type II SIUGR, balanced
karyotype, no major congenital anomalies, at least
24 months corrected age (þ or 6 weeks) and less
than 7 years and 11 months. Exclusion criteria included
families who refused the neurodevelopmental assessment and examination of their children, families
unable to complete the measures in English or
Spanish, and families who the research team was
unable to contact after making reasonable efforts to
contact them. The study was approved by the
Institutional Review Board of Sidra Medical and
Research Center in Doha, Qatar (IRB Protocol
1505000971), Children’s Mercy Hospital in Kansas City,
MO (IRB Protocol 16020132), and the University of
Southern California, Los Angeles, CA (IRB Protocol
HS-06–00194).
Parents were contacted by a member of the
research team who explained the nature of the study.
Information about the study and consent form to participate in the study was mailed or emailed to the
parents. The parents were then contacted by phone
to determine whether they wished to participate in
the study. If the family wanted to participate in the
study, they were asked if they were willing to travel to
a central location for the evaluation, or if they preferred a member of the research team to visit their
home. The parents signed the informed consent at
the time of the visit.
The children were evaluated with the Battelle
Developmental Inventory, Second Edition (BDI-2). This
tool was selected on the basis of availability of normative data, targeted age range, and the availability of
standardized versions in both English and Spanish languages. The BDI-2 involves direct individual assessment and parental interview to measure key
developmental skills in children from birth to
95 months (7 years, 11 months) [27]. Based on widely
accepted developmental milestones for children, the
BDI-2 assesses five developmental domains (personal–social, adaptive, motor, communication, and cognitive)
comprising overall development. The total BDI-2
developmental quotient score is computed as a sum
of the 5 BDI-2 subdomains, and it has a mean of 100
with a standard deviation of 15. Individual item scores
range from 0 to 2 points, with scores based on 1 of 3
predetermined criteria that include observation, parent
interview, and/or performance on a structured task.
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Neurodevelopmental impairment (NDI) was defined as
having bilateral blindness (unable to fix on or track an
object), bilateral deafness (requiring amplification),
cerebral palsy (based on physical examination), and/or
a BDI-2 total developmental quotient of <70. For the
assessment, the parents were asked to bring their
child(ren) to the clinic. If the family was unable or
unwilling to travel, arrangements were made for
the assessor to travel to the home of the family to
assess the children at their home. The BDI-2 was
administered by a clinical psychologist, developmental-behavioral pediatrician, and/or occupational therapist (OT) with experience in the administration and
interpretation of the tests.
At the assessment, the neurobehavioral specialist
administered the BDI-2 using structured administration
and parent interview. For Spanish-speaking families,
the BDI-2 was administered by a bilingual assessor.
The data were recorded in standard BDI-2 forms and
transcribed to an electronic database. The principal
investigator was blinded to the status of the subjects
(growth restricted or appropriately in utero grown
twin, or management group: expectant management
or laser).
The mothers of the children had been diagnosed
with type II SIUGR and had been randomized to either
expectant management or laser therapy. Randomization
had been conducted blindly with the use of randomization tables. Mothers randomized to expectant management were followed by their own obstetricians and
delivered for standard obstetrical indications. Mothers
that had been randomized to laser therapy had undergone selective laser photocoagulation of communicating
vessels [26] and had been referred back to their obstetricians for follow-up. Follow-up recommendations to
either group included weekly ultrasounds to assess cervical length, amniotic fluid volume, and Doppler studies
of the umbilical artery, as well as serial fetal growth
assessments every 3–4 weeks. Weekly antenatal testing
with either nonstress tests or biophysical profiles was
recommended starting at 28 weeks. Indication for delivery was left to the discretion of the referring
obstetrician.

Statistical analysis
Analyses were conducted using IBM SPSS for
Windows, version 24.0. Armonk, NY, USA: IBM Corp.
Categorical data were analyzed by the chi-square test
and Fisher’s exact test as appropriate. Interval data
were assessed for normality and analyzed with
Student’s t-test, ANOVA, or Mann–Whitney U test as
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appropriate. A p values of <.05 was considered statistically significant.
Partial funding for this study was obtained through a
charitable grant from the Brianna-Marie Foundation
(“The Foundation”), a nonprofit, tax-exempt 501-(c) three
organization. (http://www.briannamariefoundation.com/
home.html.)

Results
Figure 1 shows the study population. Of a total of 44
maternal patients referred with a diagnosis of SIUGR,
three patients were excluded at presentation: One had
a double fetal demise, one had the demise of the
SIUGR fetus, and in the third, the mother was less
than 18 years of age. Of the remaining 41 maternal
patients assessed, 26 patients (63%) had type II SIUGR
and were eligible for randomization. Six patients in
the eligible group refused randomization: four of them
elected to continue with expectant management, and
the other two requested umbilical cord occlusion of
the SIUGR twin. Of the remaining 20 type II SIUGR
patients, block randomization yielded six patients to
expectant management and 14 to laser therapy.
Although the group sizes seemed unequal, the distribution was no different than 1:1 (p¼.11 binomial test).
The study was discontinued due to poor recruitment.
Of the 15 patients ineligible for randomization, 11
patients had type I SIUGR, and four patients had type
III SIUGR. Only type II SIUGR infants are the subject of
this study.
Table 1 shows maternal demographics of the 20
randomized patients. The mean (SD) GA at diagnosis
was no different between the EM and LT groups [21.5
(2.0) versus 21.1 (2.8) weeks, p¼.7414, respectively].
However, GA at delivery was significantly lower in the
EM versus LT groups [28.3 (1.8) versus 33.4 (3.8)
weeks, p¼.0039]. Table 2 shows the indications for
delivery. Three of the 14 (21%) patients in the LT
group were delivered due to concerns regarding the
IUGR (two patients) or abruption (one patient), compared to 6/6 (100%) patients in the EM group (p¼.006,
Fisher’s exact test). Table 3 shows the perinatal outcomes. At 6 months, all 20 AGA babies were alive,
whereas 3/6 (50%) of the IUGR babies in the EM group
and 4/14 (28.6%) in the LT group were alive
(p¼.6126). Although there was no overall difference in
the survival rates of the IUGR babies between the two
groups, the timing of demise was different. In the EM
group, all the demises occurred after delivery (two
within 1 month, one within 6 months). In the LT group,
all the demises were in the fetal period.
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Figure 1. Source of patient population.
Table 1. Antenatal demographics.
Expectant management (N ¼ 6)
21.5 þ 2.0
21.9 (18.4–23.6)
28.3 þ 1.8
27.6 (26.7–31.3)
1053 þ 449
1035 (402–1785)
N¼6
589 þ 346
515 (226–1231)

Demographics
Gestational age at diagnosis (weeks)
Gestational age at delivery (weeks)
Birthweight AGA (grams)
Birthweight IUGR (grams)

Laser (N ¼ 14)
21.1 þ 2.8
21.0 (17.1–26.4)
33.4 þ 3.8
33.2 (28.3–40.0)
2236 þ 917
2208 (1070–3765)
N¼4
864 þ 255
828 (605–1195)

p Value
.7414
.0039
.0083
.1356

AGA: appropriate for gestational age twin; IUGR: growth-restricted twin.

Table 2. Indication for delivery.
Indication for delivery
Elective
AREDV
Nonreassuring fetal testing
PPROM
PTL

Expectant [6]

Laser [14]

0
2
3
1
0

4
1
2
2
5

AREDV: absent – reverse end-diastolic velocity in the umbilical artery;
PPROM: preterm premature rupture of membranes; PTL: preterm labor.

Table 4 shows the gross neurological outcomes.
There were no significant differences in the incidence
of Grade III–IV intraventricular hemorrhage or cerebral
palsy. There was no difference in neurodevelopmental
impairment (cerebral palsy, BDI-2 less than 70, blindness, and/or deafness) between the two groups.

Table 5 shows the neurodevelopmental outcomes
using the BDI-2 tool for the AGA babies. One family in
the EM group and two families in the LT group
declined BDI-2 assessment, leaving a total of 17 AGA
children (5 AGA children in the EM group and 12 AGA
children in the LT group) available for comparison.
The mean (SD) age at BDI-2 assessment was no different between the EM and LT groups [75.6 (14.4) versus
70.7 (18.2) months, p¼.5618, respectively]. There were
no significant differences in total BDI-2 scores for the
EM versus LT AGA children [97.4 (10.4) versus 98.0
(19.6), p¼.8741], nor in any of the domain scores. Only
one AGA child (1/12, 8.3%) in the LT group had a
standardized BDI-2 score < 70, compared to none
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Table 3. Perinatal outcome.
Perinatal outcome

Expectant management (N ¼ 6)

Laser (N ¼ 14)

p Value

0
0
6 (100%)
6 (100%)
6 (100%)
4 (66.7%)
3 (50.0%)

0
10 (71.4)
14 (100%)
14 (100%)
14 (100%)
4 (28.6%)
4 (28.6%)

NA
.0108
NA
NA
NA
.1611
.6126

IUFD AGA
IUFD IUGR
Survival of at least one twin
AGA alive 30 days
AGA alive 6 months
IUGR alive 30 days
IUGR alive 6 months

IUFD: fetal demise; AGA: appropriately grown twin; IUGR: growth-restricted twin.

Table 4. Gross neurological outcome.
Neurological outcome

Expectant management (N ¼ 6)

Laser (N ¼ 14)

p Value

AGA grade III–IV IVH
IUGR grade III–IV IVH

2 (33.3%)
N¼4
1
(25.0%)
0 (0%)
N¼3
1
(33.3%)
N¼5
0

0
N¼4
0

.0789
1.0000

1 (7.1%)
N¼4
0

1.0000
.4286

N ¼ 12
1
(8.3%)
N¼4
0

1.0000

AGA cerebral palsy
IUGR cerebral palsy
NDI AGA

N¼2
1 (50%)

NDI IUGR

.33

AGA: appropriate for gestational age twin; IUGR: growth-restricted twin; IVH: intraventricular hemorrhage; NDI: neurodevelopmental impairment defined as cerebral palsy, Battelle Developmental Inventory-2 (BDI-2) score less than
70, blindness, and/or deafness.

Table 5. Neurodevelopmental outcomes: AGA baby.
Battelle standardized scores AGA twin
Total
Adaptive domain
Cognitive domain
Communication domain
Motor domain
Personal social domain

Expectant management (N ¼ 5)

Laser (N ¼ 12)

p Value

100.0 þ 32.8
87.0 (67.0–143.0)
40.8 þ 15.2
45.0 (14.0–50.0)
34.2 þ 32.3
27.0 (5.0–82.0)
62.2 þ 22.1
55.0 (34.0–92.0)
11.0 þ 7.0
8.0 (5.0–19.0)
66.2 þ 34.1
75.0 (10.0–99.0)

98.4 þ 49.4
91.5 (70.0–185.0)
38.8 þ 26.7
34.5 (0.0–93.0)
46.8 þ 33.9
55.5 (0.0–93.0)
55 þ 30.9
50.0 (0.0–92.0)
39.5 þ 34.1
43.5 (0.0–91.0)
50.3 þ 29.5
75.0 (0–94)

.9161
.6723
.4927
.7110
.2910
.7612

AGA: appropriately grown twin.

Table 6. Neurodevelopmental outcomes: IUGR baby.
Battelle standardized scores IUGR twin
Total
Adaptive domain
Cognitive domain
Communication domain
Motor domain
Personal social domain

Expectant management (N ¼ 2)
72.0 þ 31.1
72.0 (50.0–94.0)
19.6 þ 27.5
19.6 (0.1–39.0)
19.6 þ 27.5
19.6 (0.1–39.0)
22.6 þ 31.7
22.6 (0.1–45.0)
1.05 þ 1.34
1.05 (0.10–2.00)
41.1 þ 57.9
41.1 (0.10–82.0)

Laser (N ¼ 4)
92.8 þ 22.1
88.5 (71.0–123.0)
38.0 þ 38.0
25.5 (9.0–92.0)
38.9 þ 31.8
33.0 (0.5–77.0)
39.8 þ 38.4
32.5 (7.0–87.0)
29.8 þ 27.9
23.0 (5.0–68.0)
45.0 þ 38.8
33.0 (16.0–98.0)

p Value
.64
.64
.48
.35
.06
.63

IUGR: growth-restricted twin.

(0/5) in the EM group, but this difference was not significant (p ¼ 1.0, Fisher’s exact test). Table 6 shows the
neurodevelopmental outcomes for the IUGR twins
(two IUGR children in the EM group and four IUGR

children in the LT group). One of the two children in
the EM group had a BDI-2 score < 70, compared to
none of the four IUGR children in the LT group
(p¼.33). No statistically significant differences were
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Figure 2. Motor developmental quotient in the IUGR children.
There was a tendency for lower scores in the expectantly managed group (p¼.062). IUGR: growth restricted twin.

Table 7. Total developmental quotient AGA versus IUGR in
paired children.
AGA

IUGR

N

Group

pa

99.67
89
105

85.83
72
92.75

6
2
4

Overall
EM
LT

.024
.416
.053

AGA: appropriately grown twin; IUGR: growth-restricted twin.
a
Student’s t-test. EM: expectant management. LT: laser therapy.

detected in total BDI-2 scores between the EM and LT
[72.0 (31.1) versus 92.8 (22.1), p¼.643], nor in any of
the domain scores, but the small number of children
limits the value of this conclusion. However, there was
a tendency for the motor development scores to be
significantly lower in the EM group than in the LT
group (69.5 versus 89.75, p¼.062, (Figure 2).
Six patients had both AGA and SIUGR babies alive
at the time of BDI-2 assessment (two in the EM group
and four in the LT group). The standardized scores
between AGA and IUGR pairs were significantly different for combined EM and LT groups, with higher AGA
scores, but still within the normal range (Table 7).
Within each group, there was a tendency for higher
AGA scores in the LT group but not in the EM group
(Table 7).

Discussion
To the best of our knowledge, this is the first study of
a US cohort of children antenatally diagnosed as having type II SIUGR who were randomly assigned to
expectant management or laser therapy and subsequently underwent formal neurodevelopmental

testing. Although the small sample size and the resulting low power of the study (5%) in detecting a true
difference in the neurodevelopmental outcome may
limit our conclusions, there are enough data to suggest that patients treated with laser therapy are likely
to have an improved outcome over those managed
expectantly. Indeed, given the statistically significant
difference in gestational age at delivery of the two
groups (28.3 versus 33.4, EM versus LT, respectively,
p¼.0039), an important clinical difference in the neurodevelopmental outcome of the AGA twin was to be
expected [28].
According to our previous work on neurodevelopmental outcomes after laser surgery for TTTS by
Vanderbilt et al., prematurity is one of the biggest risk
factors for low BDI-2 scores [27]. A recent study in
France showed an incidence of cerebral palsy of 4% in
babies born between 27 and 31 weeks compared to
1% of those born between 32 and 34 weeks [29].
Using such figures, a total of approximately 852–978
cases of type II SIUGR would be needed to show a 3%
difference in cerebral palsy between expectantly managed and laser-treated type II SIUGR patients.
There is a paucity of data regarding neurodevelopmental outcomes in patients diagnosed with type II
SIUGR. When counseling patients diagnosed with Type
II SIUGR, a clear understanding of perinatal outcomes
would be ideal. In our study, there are no differences
between expectant management and laser therapy in
the overall BDI-2 scores, nor in the individual domains,
neither for the AGA nor for the SIUGR infants. One
AGA child in the LT group (1/12, 8.3%) had a standardized score <70, whereas none of the AGA children
(0/5). This difference was not significant. We surmise
that, in a larger cohort, it is possible that neurodevelopmental differences could become apparent, in favor
of the laser-treated group, given the significantly
higher gestational age at delivery of this group.
Indeed, despite the small number of children assessed,
there was a tendency for the motor development in
the IUGR twin to be significantly better in the LT
group, compared to the EM group (p¼.062) (Figure 2).
The management of SIUGR remains controversial
[30]. Our original pilot study showed that laser ablation of the placental vascular anastomoses in SIUGR
patients was possible [1]. The goal of such proposed
treatment was to render these pregnancies as
“functionally dichorionic,” with the original purpose of
averting the adverse consequences that could result
from the demise of the SIUGR twin. Our current study
confirms such hypothesis, as none of the patients
managed with laser experienced demise of the AGA

THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE

twin after fetal demise of the SIUGR twin and the neurodevelopmental findings of the AGA twin were within
normal range. While laser therapy indeed protects the
AGA twin from the adverse consequences that could
result from the fetal demise of the SIUGR twin, we
have found in previous studies that it has two additional clinical benefits: First, laser therapy may result
in improved growth of the SIUGR twin [6]. Indeed, in a
population of 211 patients with twin–twin transfusion
syndrome, growth restriction of the donor twin was
present in 136 patients before laser, but only in 61
patients (44.8%) after laser [7]. This suggests that laser
therapy can result in improvement of fetal growth in
over 50% of patients affected by growth restriction of
a monochorionic twin. Parenthetically, this observation
suggests the role of placental vascular anastomoses in
the etiology of SIUGR itself. Second, the resulting
“functionally dichorionic” pregnancy eliminates the
need to deliver the patient for deterioration in the status of the SIUGR twin. Indeed, if demise of the SIUGR
twin was to occur before a desired gestational age,
the AGA twin would not be affected, and the pregnancy could be allowed to continue. In our experience, however, many patients choose to be delivered
on behalf of the SIUGR twin, particularly if they have
reached 27 weeks or more.
Laser therapy for SIUGR is associated with its own
set of risks and complications. In our current study, in
utero survival of the SIUGR twin was only noted in
close to 30% of SIUGR twins. This is similar to that
reported by Ishii et al. [31]. Although in our study, as
well as in that of Ishii et al. [31], 100% of the AGA
twins survived, demise of the AGA twin after laser
therapy may indeed occur and thus should be kept as
a potential complication of the surgery. Laser surgery
for SIUGR may be technically more challenging than
that for twin–twin transfusion syndrome (TTTS), given
the lack of polyhydramnios in the entry sac and the
presence of fluid in the SIUGR sac. Both of these factors, lack of polyhydramnios in the AGA twins’ sac and
the presence of fluid in the SIUGR twin’s sac, may hinder proper identification and occlusion of the vascular
anastomoses.
Our study has important strengths. First, we were
able to assess a group of infants with type II SIUGR
managed randomly antenatally to either expectant
management or laser therapy at a time when there
was equipoise in the antenatal management of these
pregnancies. In all pregnancies, both fetuses were
given a chance to survive and 100% of the AGA children did. Although the survival rate of the SIUGR twin
was approximately 30% in the LT group, this is still
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significantly better, both medically and statistically,
than if selective reduction of this fetus via cord occlusion would have been undertaken (5/14 versus 0/14,
p¼.04), as it is commonly offered to these pregnancies. Second, the clinical outcomes reflect actual current practice, as providers were allowed to make
clinical decisions as needed after randomization. Third,
although the actual neurodevelopmental outcomes
did not differ between the groups, overall they reflect
a good prognosis for these extremely complicated
monochorionic twin pregnancies. Given the significantly different gestational ages at delivery between
the groups, we would expect clinical differences to
become apparent with a larger cohort, in favor of
laser-treated patients. Lastly, the age at which the
infants were tested, with a mean of 70–75 months,
allowed time for any potential neurodevelopmental
abnormality to become manifest. Our study’s biggest
limitation is the small cohort size, which is not uncommon in our field.
In conclusion, no neurodevelopmental differences
were observed in children who were antenatally managed either expectantly or with laser therapy after
being diagnosed with type II SIUGR. However, we
would suspect that such differences may become
apparent in larger cohorts, in favor of laser-treated
patients, given the significantly higher gestational age
of delivery of the laser group.
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